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We reviewed neuromedin U (NMU) and neuromedin S (NMS) involvement in the regulation
of the hypothalamo–pituitary–adrenal (HPA) axis function. NMU and NMS are structurally
related and highly conserved neuropeptides. They exert biological effects via two GPCR
receptors designated as NMUR1 and NMUR2 which show differential expression. NMUR1
is expressed predominantly at the periphery, while NMUR2 in the central nervous system.
Elements of the NMU/NMS and their receptors network are also expressed in the HPA
axis and progress in molecular biology techniques provided new information on their
actions within this system. Several lines of evidence suggest that within the HPA axis
NMU and NMS act at both hypothalamic and adrenal levels. Moreover, new data suggest
that NMU and NMS are involved in central and peripheral control of the stress response.
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INTRODUCTION
In search for new biologically active peptides, the group of
Minamino, Kangawa, andMatsuo in the 1980s isolated numerous
small neuropeptides from porcine spinal cord. All of them exerted
potent smooth-muscle stimulating activity. These short peptides
have been named neuromedins (Minamino et al., 1985). Their
sequences and biological activities are similar to some known
neuropeptides and therefore they are commonly divided into four
groups (classes):
Bombesin-like neuromedins—neuromedin B (NMB) and neu-
romedin C (NMC) (Minamino et al., 1983, 1984b).
Kassinin-like neuromedins—neuromedin K (NMK) and neu-
romedin L (NML) (Kangawa et al., 1983; Minamino et al., 1984a).
Neurotensin-like neuromedins—neuromedin N (NMN)
(Minamino et al., 1984c).
Neuromedins U (NMU), for which no substantial homology with
other known neuropeptides was found (Minamino et al., 1985).
This group, however, was expanded in 2005, when Mori et al.
(2005, 2008) isolated neuromedin S (NMS) from rat brain. NMS
is composed of 36 amino acid residues and both peptides share
the same amidated C-terminal heptapeptide. Furthermore, both
NMU andNMS appeared to be endogenous ligands for the orphan
G protein-coupled receptors FM-3/GPR66 and FM-4/TGR-1,
identified earlier as type-1 and type-2 NMU receptors (NMUR1
and NMUR2), respectively (Tan et al., 1998; Howard et al., 2000;
Raddatz et al., 2000; Mori et al., 2005).
Abbreviations: CRH, corticotropin releasing hormone; GPCR, G protein coupled
receptor; HPA, hypothalamo–pituitary–adrenal; icv, intracerebroventrical; iPVN,
intraparaventricular nucleus; KO, knock out; NMS, neuromedin S; NMU, neu-
romedin U; NMUR1, neuromedin U receptor 1; NMUR2, neuromedin U receptor
2; PCR, polymerase chain reaction; PVN, paraventricular nucleus; QPCR, quanti-
tative real time polymerase chain reaction; RT-PCR, reverse transcription PCR; sc,
subcutaneously; WT, wild type.
Identification of specific NMU receptors (NMUR1 and
NMUR2) and its anorexigenic action have enhanced interest in
physiological role of NMU and NMS (Howard et al., 2000; Ida
et al., 2005). Advances in these studies were recently reviewed
(Brighton et al., 2004; Mori et al., 2008; Mitchell et al., 2009a;
Budhiraja and Chugh, 2009). Present review, on the other hand,
will focus on expression and of role of NMU/NMS system in
hypothalamo–pituitary–adrenal (HPA) axis functioning, updat-
ing thus our earlier reviews (Malendowicz andMarkowska, 1994;
Malendowicz, 1998; Malendowicz et al., 2013).
ISOLATION, STRUCTURE, AND SYNTHESIS OF NMU AND
NMS
Originally NMU was isolated from porcine spinal cord in
two molecular forms, one containing 25 (NMU25) and the
other 8 (NMU8) amino acid residues (Minamino et al., 1985).
Subsequently NMU was isolated from other vertebrates, among
them humans (Austin et al., 1995), rat (Conlon et al., 1988),
guinea pig (Murphy et al., 1990), dog (O’Harte et al., 1991a),
rabbit (Kage et al., 1991), chicken (O’Harte et al., 1991b; Domin
et al., 1992), frogs—Rana temporaria, Litoria caerulea, and
Bombina maxima (Domin et al., 1989b; Salmon et al., 2000; Lee
et al., 2005), and goldfish (Maruyama et al., 2008). Amino acid
sequences of NMU from different species are shown in Figure 1.
In the mammalian NMUs a common C-terminal sequence—
Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2—contains the active site of
the neuropeptide, which is formed by the amino acid residues
between positions 2 and 8 (Hashimoto et al., 1991; Sakura et al.,
1991). Recent data indicate that in most species studied, the five
amino acids at the C-terminus of the NMUs are totally conserved,
suggesting that this region is of major importance for biologi-
cal activity (Lo et al., 1992; Brighton et al., 2004; Mitchell et al.,
2009b). Amidation of the C-terminus of NMU is required for
receptor activation (for review see Brighton et al., 2004).
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FIGURE 1 | Amino acid sequences of neuromedin U from some mammalian, avian, piscine, and amphibian species. The box, highlighting the C-terminal
pentapeptide, shows conservation of this sequence in vertebrates, except of goldfish. From Mitchell et al. (2009a), modified. Amino acid sequences were
acquired from NCBI. Numbers after NMU denote peptide length.
Unexpectedly, in 2005, Mori et al. (2005) isolated from the
rat brain a new 36 amino acid peptide related to NMU, which
appeared to be another endogenous ligand of FM-4/TGR-1 recep-
tor. This neuropeptide is highly expressed in the suprachiasmiatic
nucleus of the hypothalamus and therefore was designed as NMS.
Human NMS, on the other hand, is composed of 33 amino
acid residues. All NMS share a C-terminal core structure with
NMU. NMU and NMS share the same amidated C-terminal hep-
tapeptide and bind to the same receptors NMUR1 and NMUR2.
Amino acid sequences of NMS from different species are shown
in Figure 2.
It should be emphasized that NMU andNMS genes are located
on different chromosomes (NMU on 4q12 and NMS on 2q11.2)
(Mori et al., 2005). Moreover, evidences indicate that during the
FIGURE 2 | Amino acid sequences of neuromedin S from some mammalian and amphibian species. The box, highlighting the C-terminal decapeptide,
shows conservation of this sequence in vertebrates. NMU and NMS share the same amidated C-terminal heptapeptide. Amino acid sequences were acquired
from NCBI. Numbers after NMS denote peptide length.
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process of evolution NMU and NMS genes had already diverged
at the level of the Amphibia (Chen et al., 2006).
In humans both NMU and NMS genes are composed of 10
exons and 9 introns. The mRNA lengths encoded by these genes
are 816 and 485 bp, respectively. The exon–intron boundaries in
the NMU and NMS prepro-proteins are comparably conserved
(Mori et al., 2008). General structures of encoded prepro-NMU
and prepro-NMS are shown in Figure 3.
NMU AND NMS RECEPTORS
Early studies revealed the presence of highly specific 125I-NMU
binding sites on membranes prepared from the rat uterus. The
binding was saturable and specific and Scatchard analysis sug-
gested a single class of binding site with a Kd of 0.35 nM (Nandha
et al., 1993).
By means of modern molecular biology techniques two recep-
tors for NMU were identified. In 1998, Tan et al. (1998) cloned
a GPCR (FM-3) from human and murine cDNA libraries. This
DNA segment has homology to the growth hormone secreta-
gogue receptor and the neurotensin receptor. Subsequently, by
means of a “reverse pharmacological” method NMU was identi-
fied as an endogenous ligand for the orphan human GPCR, FM-3
(or GPR66) (Fujii et al., 2000; Hedrick et al., 2000; Hosoya et al.,
2000; Howard et al., 2000; Kojima et al., 2000; Raddatz et al.,
2000; Shan et al., 2000; Szekeres et al., 2000). After identifica-
tion of the second NMU receptor, the first one had been named
NMUR1.
The NMUR2 (FM-4, TGR1) gene, on the other hand,
was identified based on its sequence similarity with NMUR1
(Hosoya et al., 2000; Howard et al., 2000; Raddatz et al.,
2000; Shan et al., 2000). NMUR1 gene is located on human
chromosome 2—position q37.1 and NMUR2 gene on chromo-
some 5—position q33.1 (Mitchell et al., 2009a).
In humans NMUR1 gene consists of 3 exons and 2 introns, the
size of encoded mRNA is 3274 bp and the receptor is composed
of 426 aa residues. NMUR2 gene, on the other hand, consists of
4 exons and 3 introns. The size of its mRNA is 2067 bp and the
receptor is composed of 415 aa residues (Figure 4).
NMS has also been identified as an endogenous ligand of
NMUR1 and NMUR2 receptors and some data indicate that
FIGURE 3 | Schematic structure of prepro-NMU and prepro-NMS in
humans. Data from Protein Knowledgebase (UniProtKB) P48645 and
Q5H8A3, respectively. Schematic structure of prepro-NMU is modified
from Austin et al. (1995). Numbers refer to residues and cleavage sites are
given in red. Asterisk marks amidated asparagine.
NMUR2 has greater affinity to NMS than NMU (Mori et al.,
2005).
Interaction of NMU and NMS with their receptors results in
intracellular calcium mobilization and subsequent stimulation of
inositol phosphates. These effects are mediated by both Gq/11 and
Gi/0 proteins (Raddatz et al., 2000; Shan et al., 2000; Szekeres
et al., 2000; Funes et al., 2002; Mori et al., 2005; Maruyama et al.,
2011). Moreover, both neuromedins are also able to activate the
mitogen activated protein kinase ERK1 and ERK2 (Brighton et al.,
2004).
EXPRESSION OF NMU AND NMS AND THEIR RECEPTORS IN
THE HYPOTHALAMO–PITUITARY–ADRENAL AXIS
HYPOTHALAMUS
NMU and NMS
Soon after NMU identification, high concentrations of NMU-
like immunoreactivity were found in extracts of the rat, mouse,
and human hypothalamus (Domin et al., 1986, 1988). In rat
hypothalamus concentration of NMU-like immunoreactivity was
reported as 31.2 ± 5.6 pmol/g (nearly 6 times higher than in
the anterior pituitary lobe). Subsequent immunohistochemical
studies demonstrated the presence of NMU-like substances in
the hypothalamic paraventricular (PVN) and arcuate nucleus of
the rat (Honzawa et al., 1987; Ballesta et al., 1988; Steel et al.,
1988). On the other hand, molecular biology techniques demon-
strated low to moderate levels of NMU mRNA in rat (RT-PCR)
and human (QPCR) hypothalamus (Fujii et al., 2000; Szekeres
et al., 2000). Single-cell reverse transcription-multiplex poly-
merase chain reaction (single-cell RT-mPCR) technique revealed
that 14.7% parvocellular neurons of the rat PVN expressed NMU
mRNA (Chu et al., 2012).
NMU mRNA is present in hypothalamus of WT mice and, in
contrast, NMU mRNA could not be detected in NMU KO mice
(Fukue et al., 2006).
In the frog (Rana esculenta) NMU-like immunoreactivity was
observed in perikaria of the dorsal nucleus of the hypothalamus
and the caudal part of the infundibulum (Maderdrut et al., 1996).
Although authors emphasize that this pattern of immunoreactiv-
ity distribution differs notably from that seen in mammals, it is
necessary to emphasize that the ventral infundibular nucleus of
the frog is homologous to the mammalian arcuate nucleus (Neary
and Northcutt, 1983; Ten Donkelaar, 1998).
The highest expression of NMS mRNA was found by RT-
PCR in rat hypothalamus (Mori et al., 2005). Subsequently,
in situ hybridization demonstrated that this neuropeptide was
specifically expressed in the hypothalamic suprachiasmatic nuclei
(SCN). In the rat hypothalamus expression of NMS gene was
nearly 3-fold higher than that of NMU gene (Rucinski et al.,
2007). During postnatal development levels of NMS mRNA
attained maximum at prepubertal stage and adulthood (Vigo
et al., 2007).
NMU receptors
Earliest studies revealed that NMUR1 is expressed predominantly
in periphery while NMUR2 in the central nervous system (for
review see Brighton et al., 2004; Mitchell et al., 2009a). In agree-
ment with this principle in the rat hypothalamus, by means
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FIGURE 4 | Schematic representation of human NMUR1 and NMUR2 receptors. NMUR1 receptor is composed of 426 amino acid residues while NMUR2
of 415. Amino acid sequences were acquired from NCBI, accession numbers AAG24793.1 and EAW61653.1, respectively.
of QPCR Raddatz et al. (2000) demonstrated high expression
of NMUR2 and a notably lower one of NMUR1. This find-
ing was confirmed by numerous groups (Fujii et al., 2000;
Howard et al., 2000; Qiu et al., 2005; Rucinski et al., 2007; Vigo
et al., 2007). NMUR2 gene is also expressed in the PVN. By
means of the single-cell RT-mPCR analysis (multiplex) Qiu et al.
(2005) demonstrated that NMU-sensitive PVN neurons abun-
dantly expressed NMUR2 mRNA but expressed NMUR1 mRNA
to a lesser extent or not at all.
Detailed mapping of NMUR2 mRNA expression in the rat
brain by in situ hybridization revealed the most intense signal
in ependymal cells of the third ventricle and moderate signal in
the PVN (Guan et al., 2001; Graham et al., 2003). Presence of
NMUR2 receptors in these regions of the brain had also been
confirmed by receptor autoradiography (Mangold et al., 2008).
Similar pattern of NMU receptor expressions is observed in
human hypothalamus, with high expression of NMUR2 and a
negligible one of NMUR1 (Szekeres et al., 2000; Gartlon et al.,
2004).
PITUITARY GLAND
NMU and NMS
High concentrations of NMU-like immunoreactivity were found
in the pituitary gland of the rat as early as in 1987 (Domin et al.,
1987, 1988, 1989a). In rat anterior lobe concentration of NMU-
like immunoreactive substances was 6.3 pmol/gland (mean) while
in posterior lobe 0.3 pmol/gland only. Furthermore, Northern
blot analysis using total RNA extracted from rat anterior pituitary
demonstrated high levels of NMU mRNA in the gland (Lo et al.,
1992).
High concentrations of NMU protein in rat pituitary gland
are accompanied by high expression of NMU gene (Fujii et al.,
2000). High expression of this gene in anterior pituitary lobe of
the rat was confirmed by QPCR (Rucinski et al., 2007; Shimizu
et al., 2008). It should be emphasized that NMU mRNA is also
expressed in cultured pituitary cells of the rat. Using quantitative
in situ hybridization, high concentration of NMU transcripts was
also found in part tuberalis of the rat pituitary (Ivanov et al., 2002;
Nogueiras et al., 2006).
Immunohistochemistry demonstrated the presence of NMU-
immunoreactive substances in the intermediate and the anterior
pituitary gland lobes of mouse, rat, and human (Ballesta et al.,
1988; Steel et al., 1988). Electron microscopy studies revealed
NMU-like immunoreactivity in some thyrotropes and most cor-
ticotropes of the rat pituitary gland. NMU is colocalized with
galanin and ACTH in the same secretory granules (Cimini et al.,
1993; for review see Malendowicz, 1998; Cimini, 2003).
In developing rat NMU-immunopositive cells appear in ante-
rior pituitary at day E15 (Cimini, 2003). Their number increases
at day E20 and then decreases. More than 60% of NMU-
immunoreactive cells contain ACTH at E15, and, after falling to
about 40% at E16, this value is more or less constant until E21.
NMU mRNA is expressed in pituitary gland of WT mice, but
in contrast, NMUmRNA could not be detected in NMUKOmice
(Fukue et al., 2006).
Expression of NMS gene in rat pituitary gland was found by
Mori et al. (2005). In rat anterior pituitary expression level of
NMS gene however, was notably lower than that of NMU gene
(Rucinski et al., 2007).
NMU receptors
Conflicting data were reported on expression of NMUR1 and
NMUR2 in pituitary gland. By means of QPCR low expression of
both receptors in human pituitary gland was reported by Raddatz
et al. (2000). These data were confirmed by other groups (Shan
et al., 2000; Gartlon et al., 2004).
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The earliest studies did not reveal NMUR1 gene expression in
the rat pituitary gland while that of NMUR2 was very low (Fujii
et al., 2000; Gartlon et al., 2004). On the other hand, in rat adeno-
hypophysis expression of NMUR1 gene, but not of NMUR2 was
observed by our group (Rucinski et al., 2007).
Expression of both NMUR1 and NMUR2 genes was observed
in mouse pituitary gland of both WT and NMU KOmice (Fukue
et al., 2006).
ADRENAL GLAND
Only scanty data are available on expression of NMU–NMS and
their receptors in adrenal glands. Very low levels of NMU mRNA
in the rat adrenal were reported by Fujii et al. (2000). Detailed
studies on rat adrenal gland revealed very low expression of NMU
and NMS genes at mRNA levels (Rucinski et al., 2007).
In human adrenal gland both NMUR2mRNA (PCR) and pro-
tein (dot blot method) were identified in 2000 (Raddatz et al.,
2000; Shan et al., 2000).
In the rat adrenal gland NMUR2 mRNA could not be demon-
strated (Hosoya et al., 2000; Fujii et al., 2000). In immature
rat adrenal NMUR1 was expressed at both mRNA and protein
(immunohistochemistry) levels while the signal from NMUR2
was absent. NMUR1 mRNA was detected in all adrenocortical
zones and in medulla of the gland (Ziolkowska et al., 2008).
Moreover, the presence of NMUR1 mRNA in isolated zona
glomerulosa and fasciculata/reticularis cells rules out the possi-
bility that the expression was due to the presence in the speci-
mens assayed of the non-parenchymal components of the gland.
Expression of NMUR1 as mRNA and protein was demonstrated
in adrenal gland of intact rat, in enucleation-induced regenerating
gland, in hemiadrenalectomized animals (compensatory adrenal
growth) as well as in ACTH-stimulated one (Trejter et al., 2008,
2009; Malendowicz et al., 2009).
NMU AND NMS IN THE
HYPOTHALAMO–PITUITARY–ADRENAL AXIS FUNCTIONING
HYPOTHALAMUS
The above described localization of elements of NMU/NMS and
NMUR2 system in hypothalamus forms a base of regulation by
NMU and NMS of HPA axis functioning.
The earliest experiments with intracerebroventricular (icv)
injection of NMU demonstrated a strong increase in Fos-
immunoreactive nuclei in the PVN and supraoptic nucleus
(SON) of the rat hypothalamus (Niimi et al., 2001; Ozaki et al.,
2002). Almost all CRH-containing neurons in the parvocellular
divisions of the PVN expressed Fos-like immunoreactivity 90min
after icv administration of NMU (Yokota et al., 2004).
Subsequent studies demonstrated direct NMU effects on CRH
and arginine vasopressin (AVP) release by rat hypothalamic
explants in vitro (Wren et al., 2002). At the 100 nMNMU concen-
tration CRH and AVP release was nearly doubled when compared
to controls. Moreover, results of whole cell patch-clamp record-
ings revealed that NMUdirectly depolarized the subpopulation of
PVN parvocellular, but not magnocellular neurons via enhance-
ment of the hyperpolarization-activated inward current (Qiu
et al., 2003). Direct effects of both neuromedins on PVN was also
suggested by in vitro electrophysiological studies which showed
that NMU and NMS increased the neuronal firing rates in both
arcuate and PVN nuclei slices (Nakahara et al., 2010).
NMU also regulates HPA axis in birds. Icv administration of
NMU in chicks significantly upregulated mRNA expression of
CRH in the hypothalamus (Kamisoyama et al., 2007).
NMS likewise affects CRH neurons in PVN. In the rat icv
administration of this neuromedin increased POMC mRNA
expression in the arcuate nucleus and CRH mRNA in the PVN
(Ida et al., 2005; Nakahara et al., 2010). NMS notably stimulated
Fos-immunoreactive cells in both hypothalamic nuclei. NMS also
significantly increased firing rate of PVN cells. Stimulating effects
of NMS on Fos-immunoreactive cells of the PVN was confirmed
by another group (Sakamoto et al., 2007, 2008).
PITUITARY
Expression of NMUR1 in pituitary gland and colocalization of
NMU and ACTH in pituitary corticotropes suggest NMU and
NMS involvement in regulation of ACTH secretion. Regarding
this, there is a growing body of evidence that in the rat NMU
administered icv, into PVN or subcutaneously increases blood
ACTH concentrations, via stimulation of CRH release.
First reports demonstrated that a single sc injection of NMU8
resulted in a transient increase in ACTH blood concentration
while after 2–6-day treatment (low NMU8 dose) blood ACTH
level remained unchanged (Malendowicz et al., 1993, 1994b;
Trejter et al., 2009). Only the higher dose of NMU8 (6µg/
100 g/day for 6 days) increased the level of circulating ACTH.
In the rat unilateral adrenalectomy notably increased plasma
ACTH concentrations and NMU administration (sc) into hemi-
adrenalectomized rats did not significantly change corticotropin
levels (Malendowicz et al., 2009).
In the rat icv administration of NMU (0.1, 1, and 3 nmol/rat)
resulted in a dose-dependent increase of plasma ACTH concen-
trations, an effect significantly reduced by pretreatment with anti-
NMU IgG (Ozaki et al., 2002). Similar dose-dependent effects of
NMU on plasma ACTH concentrations were found after iPVN
neuropeptide administration (Wren et al., 2002). Again, chronic
iPVN NMU administration (twice-daily of 0.3 nmol NMU for
7 days) did not change plasma ACTH concentrations (Thompson
et al., 2004). Only one group was unable to demonstrate stimu-
lating effect of icv administered NMU on plasma ACTH concen-
trations in the rat (Rokkaku et al., 2003).
Unfortunately, no studies have as yet investigated direct effects
of NMU andNMS on pituitary ACTH secretion. Our preliminary
data indicate that neither NMU nor NMS affect ACTH release by
quarters of the rat adenohypophysis, while the response to CRH
was normal. This observation may suggest that observed in vivo
stimulating effect of NMU/NMS on ACTH secretion is mediated
via hypothalamus.
ADRENAL
Potent stimulating effects of exogenous NMU on adrenocorti-
cal steroid secretion in the rat have been described as early as
in 1993. A single sc injection of NMU resulted in a transient
increase in ACTH blood concentration (between 3 and 12 h) and
a sustained (24 h) elevation of plasma corticosterone concentra-
tion (Malendowicz et al., 1993, 1994b). These data demonstrated
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stimulating effect of neuropeptide on adrenal cortex, possibly
partially due to the direct effect of NMU on the gland.
In subsequent searches for mode of NMU action on corticos-
teroid secretion our group found that NMU had no effect on
basal and ACTH-stimulated corticosterone secretion by freshly
isolated or cultured inner zone adrenocortical cells, nor did it
change their cytosolic Ca2+ concentration (Malendowicz et al.,
1994b; confirmed by Ziolkowska et al., 2008). However, this
neuropeptide stimulated corticosterone output by adrenal slices,
but not by fragments of adrenocortical autotransplants lack-
ing medullary chromaffin cells (Malendowicz et al., 1994a).
Detailed analysis revealed that at all concentrations tested
NMU increased basal pregnenolone and total post-pregnenolone
steroid output by gland slices containing both cortex and
medulla. The increase in total post-pregnenolone steroid out-
put induced by low concentrations of NMU8 was due to sim-
ilar rises in the production of non-18-hydroxylated steroids;
conversely, that provoked by higher concentrations of the pep-
tide was almost exclusively caused by the rise in the yield
of 18-hydroxylated steroids. The stimulating effect of NMU8
on pregnenolone output was blocked by both alpha-helical-
CRH and corticotropin-inhibiting peptide, which are compet-
itive inhibitors of CRH and ACTH, respectively. These data
suggest that NMU affects corticosteroid secretion indirectly by
acting on the medullary chromaffin cells, which in turn may
paracrinally stimulate cortex of the gland. We also suggested
that the medullary mediator of NMU action on adrenal cortex
may activate 18-hydroxylation and aldosterone synthase activity.
On the other hand, we cannot rule out the possibility of NMU
action on adrenal cortex via stimulation of adrenaline secretion
by adrenal medulla. Recently it has been demonstrated that cen-
trally administered NMU evokes secretion of adrenaline from
the adrenal medulla (Sasaki et al., 2008). Medullary adrenaline
may in turn modulate secretion of corticosteroids (for review see
Nussdorfer, 1996; Bornstein et al., 1997; Ehrhart-Bornstein et al.,
1998).
Stimulating effects of NMU on corticosteroid secretion also
were observed after icv or iPVN neuropeptide administration.
In the rat acute iPVN administration of NMU dose-dependently
increased plasma corticosterone concentrations (Wren et al.,
2002). Similar effect was observed after icv NMU administration
(Ozaki et al., 2002). In contrast, another group reported lack of
icv NMU administration effects on plasma corticosterone levels
(Gartlon et al., 2004).
Stimulating effects of icv administered NMU on plasma corti-
costerone levels were confirmed by experiments with anti-NMU
IgG (Jethwa et al., 2006). In rats administration of anti-NMU IgG
significantly attenuated the dark phase rise in plasma corticos-
terone concentrations.
In contrast to acute administration, chronic iPVN adminis-
tration of NMU produced an elevation of plasma corticosterone
levels while plasma ACTH concentrations remained unchanged
(Thompson et al., 2004). Thus, in chronically NMU administered
rats elevated plasma corticosterone levels, not accompanied by
increased ACTH concentrations, were independent of the mode
of NMU administration (sc vs iPVN) (Malendowicz et al., 1993,
1994b; Thompson et al., 2004).
The stimulating effect of sc administered NMU on plasma
corticosterone concentrations also was found in rats during
enucleation-induced regeneration, as well as in rats treated with
low ACTH doses (Trejter et al., 2008, 2009). On the other hand,
NMU8 administration to immature rats was found to raise aldos-
terone, but not corticosterone concentrations (Ziolkowska et al.,
2008).
NMS, like NMU also stimulates corticosteroid secretion. In
rats icv NMS administration resulted in nearly 5-fold increase in
plasma corticosterone concentrations and the effect was depen-
dent on neuropeptide dose (Jászberényi et al., 2007). Likewise,
in castrated Holstein steers both NMS and NMU evoked a dose-
related increase in plasma cortisol concentrations (Yayou et al.,
2009). Of interest is that also in chicks icv NMS administration
stimulated corticosterone release (Tachibana et al., 2010).
In contrast to the above described NMS effects on corticos-
terone/cortisol secretion, an opposite effect was seen in Rhesus
monkeys (Jahan et al., 2011). In their experiments NMS was
infused through a teflon cannula implanted into saphenous vein.
Blood samples were collected 45min before and 120min after
NMS administration at 15min intervals. Under these conditions
NMS resulted in a significant decrease in plasma cortisol levels
at 40 and 60 nmol doses while a non-significant difference was
observed at 20 nmol. This unexpected finding may suggest that in
non-human primates NMS exerts inhibitory effect on HPA axis
functioning. However this finding remains to be confirmed.
Recent data also demonstrated direct stimulating effect of
NMU on proliferative activity of immature rat inner adreno-
cortical cells in primary culture (Ziolkowska et al., 2008).
Moreover, in enucleation-induced adrenal regeneration NMU
notably enhanced proliferative activity of adrenocortical cells
(Trejter et al., 2008). A similar stimulating effect of sc adminis-
tered NMU on proliferative activity (metaphase index) was seen
in ACTH treated rats (Trejter et al., 2009). In contrast, in hemia-
drenalectomized rats NMU notably inhibited adrenocortical cell
proliferation in both zona glomerulosa and zona fasciculata, as
assessed by the metaphase index (Malendowicz et al., 2009). Since
these effects were independent of changes in blood ACTH, they
could reflect an interaction of NMUwith the neural system inner-
vating the adrenal gland, which is responsible for compensatory
adrenal growth.
INVOLVEMENT OF NMU AND NMS IN THE STRESS
RESPONSE
As it follows from the above presented data, NMU and NMS are
linked to the HPA axis functioning. Independently of mode of
administration (icv, iPVN, or sc) NMU activates CRH contain-
ing neurons and stimulates CRH secretion, which in turn triggers
pituitary ACTH and adrenal corticosterone/cortisol secretion. In
this regard it is not astonishing that NMU and NMS are involved
in central and peripheral control of the stress response. These
studies were initiated by Hanada et al. (2001) who observed
stress-related behavior (gross locomotor activity, face washing
and grooming) in icv NMU administered rats. This response
was attenuated by pretreatment with alpha-helical CRH (antag-
onist of CRH) or anti-CRH IgG. Furthermore, NMU-induced
increases in oxygen consumption and body temperature were
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attenuated in CRH KO mice. Subsequent studies demonstrated
that blood corticosterone levels were significantly increased after
10min of immobilization stress in wild-type mice, but not
in NMU KO mice (Nakahara et al., 2004). Excessive groom-
ing induced by icv NMU administration were abolished in the
NMUR2 KO mice, an observation suggesting that NMUR2 plays
a decisive role in stress/anxiety induction (Zeng et al., 2006).
Stress related behavior induced by icv NMU or NMS admin-
istration was also observed in cattle (Yayou et al., 2009).
Administration of both neuropeptides tended to shorten the
duration of lying and increase the number of head shaking in
studied cattle. These behavioral changes were accompanied by
increased levels of plasma cortisol.
CONCLUDING REMARKS
The above reviewed data clearly demonstrate NMU and NMS
involvement in regulation of HPA axis growth and functions.
However, their mechanism of action is far from being completely
understood. The available experimental data suggest that within
theHPA axis these neuromedinsmay exert both endocrine and/or
paracrine/autocrine effects on target cells.
Endocrine effects of discussed neuropeptides require their
release into the bloodstream. Only scanty data are available on
NMU and NMS presence in general circulation. Manufacturers’
manuals for various kits contain data on NMU and NMS con-
centration in plasma and comparable figures are shown in clinical
studies (Ketterer et al., 2009). However, experimental data suggest
that neither endogenous NMU nor NMS are circulating, at least
in the rat (Peier et al., 2009). Furthermore, in general circulation
the biological half-life of NMU is shorter than 5min.
At the hypothalamus level the actions of NMU and NMS
are rather well documented. Stimulation of CRH, arginine-
vasopresssin and oxytocin release both in vivo and in vitro
activates HPA axis and apart from elevation of ACTH and
corticosterone/cortisol secretion, triggers behavioral parameters
typical for stress reaction.
More puzzling is the effect of NMU on pituitary gland. As
discussed earlier, in pituitary gland high levels of NMU are
present, and the gland contains high concentration of NMU-like
immunoreactive substances and is provided with NMUR1 recep-
tor. NMU is colocalized with ACTH and numerous NMU-like
immunoreactive cells are present in human extrapituitary corti-
cotropinomas (Steel et al., 1988). Denef (2008) suggests that in
the pituitary NMUmay paracrinally regulate function of adjacent
cells and a similar mode of action may be present in extrapituitary
corticotropinomas. So far, direct effects of NMU/NMS on pitu-
itary ACTH secretion have not been reported. Our preliminary
data indicate that neither NMU nor NMS affect ACTH release
by quarters of the rat adenohypophysis. It remains to be estab-
lished whether inability of NMU and NMS to directly stimulate
ACTH release from pituitary gland may be caused by possible
high receptor occupancy by endogenous NMU.
In view of these findings, questions arise concerning the possi-
ble role of NMU in pituitary tumor formation. In their review on
pituitary tumorogenesis Korbonits et al. (2004) mention NMU
only as a potential messenger in the anterior pituitary. Thus, the
possible role of NMU in development of pituitary and extrapitu-
itary corticotropinomas requires further investigation. As far as
endocrine system is concerned, an elevated expression of NMU
gene was found in human ovarian cancer cell lines (Euer et al.,
2005).
The available experimental data suggest that at the adrenal
level NMU affects the steroid secretion indirectly by acting on the
medullary chromaffin cells. On the other hand some data sug-
gest direct effect of neuromedin on proliferation and growth of
rat adrenocortical cells.
Thus, although great progress has been made in understand-
ing NMU and NMS action within the HPA axis during the past
years, much remains to be learned about their mechanisms of
action within this system. Recent development of a metaboli-
cally stable analog of NMU, based on derivatization of the native
peptide with high molecular weight poly(ethylene) glycol (PEG)
(“PEGylation”) may be helpful in these attempts (Ingallinella
et al., 2012).
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